Waldenstrom Macroglobulinemia (WM)
Oncology·MeSH: Waldenstrom Macroglobulinemia
Prevalence
5.0 / 100K
1 drug in development·1 company·2 clinical trials
Drug Pipeline by Phase
Phase 1(1)
| Drug | Company |
|---|---|
| mb-106 | MUSTANG BIO, INC. (MBIO) |
Frequently asked questions
How many drugs are in development for Waldenstrom Macroglobulinemia (WM)?
BioSniper tracks 1 drug in development for Waldenstrom Macroglobulinemia (WM) across 1 company.
How many clinical trials target Waldenstrom Macroglobulinemia (WM)?
There are 2 clinical trials targeting Waldenstrom Macroglobulinemia (WM) tracked by BioSniper.
What is the prevalence of Waldenstrom Macroglobulinemia (WM)?
The estimated prevalence of Waldenstrom Macroglobulinemia (WM) is approximately 5.0 per 100,000 population.
Deep-dive into Waldenstrom Macroglobulinemia (WM)
Full trial data, competitive analysis, and AI-powered pipeline tracking.
Start Free Analysis